A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
Latest Information Update: 15 Oct 2025
At a glance
- Drugs JKN 2501 (Primary)
- Indications Bacterial infections; Intra-abdominal infections; Respiratory tract infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors Joincare Pharmaceutical
Most Recent Events
- 15 Oct 2025 New trial record